Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based specialist drug development company. The Company is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused advancing the dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the cytokine storm immune system overreaction to Covid-19 and other viral infections (SDC-1801) and cancer immunotherapy (SDC-1802). The Company has interest in SRA737, which is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and deoxyribonucleic (DNA) damage repair mechanisms. In addition, the Company manufactures SDC-1801 drug substance and oral capsule formulation under good manufacturing practice (GMP) conditions is on track to enable the Phase Ia trial.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.81m
- Incorporated2004
- Employees6.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttp://www.sareum.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open Orphan PLC | 32.93m | -1.06m | 61.05m | 218.00 | -- | 2.94 | 20.79 | 1.85 | -0.0016 | -0.0016 | 0.0491 | 0.031 | 0.7473 | -- | 2.95 | 151,045.90 | -2.41 | -21.58 | -4.85 | -39.82 | -- | -- | -3.23 | -25.22 | 1.16 | 2.53 | 0.0981 | -- | 78.93 | 20.23 | 99.31 | -- | 62.75 | -- |
| 4Basebio PLC | -100.00bn | -100.00bn | 70.83m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -26.84 | -- | -349.93 | -- | -- | -- |
| Eco Animal Health Group Plc | 82.20m | -686.00k | 76.19m | 221.00 | -- | 0.9284 | 59.15 | 0.9269 | -0.0101 | -0.0101 | 1.21 | 1.21 | 0.7132 | 1.86 | 2.74 | 371,923.10 | -0.6117 | 7.78 | -0.845 | 10.06 | 42.75 | 46.98 | -0.8577 | 10.42 | 2.42 | 69.12 | 0.0198 | 53.51 | -22.17 | 6.00 | -109.35 | -- | -18.83 | -- |
| Arecor Therapeutics PLC | 1.39m | -7.43m | 80.79m | 37.00 | -- | 5.06 | -- | 58.08 | -0.3249 | -0.3249 | 0.0604 | 0.5237 | 0.0681 | -- | 0.6841 | 37,594.05 | -36.37 | -- | -41.23 | -- | -- | -- | -534.19 | -- | 6.24 | -535.05 | 0.0115 | -- | -31.79 | -- | -124.13 | -- | -- | -- |
| e-Therapeutics plc | 477.00k | -8.07m | 95.20m | 32.00 | -- | 3.40 | -- | 199.59 | -0.0169 | -0.0169 | 0.001 | 0.0544 | 0.0217 | -- | 3.31 | 14,906.25 | -36.62 | -37.71 | -38.29 | -40.40 | 100.00 | 100.00 | -1,691.82 | -1,812.91 | -- | -- | 0.0239 | -- | 50.47 | -- | -119.06 | -- | 42.31 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -21.37m | 104.37m | 37.00 | -- | -- | -- | -- | -0.4063 | -0.4063 | 0.00 | -0.0845 | 0.00 | -- | -- | 0.00 | -166.26 | -165.50 | -342.16 | -391.61 | -- | -- | -- | -487,178.90 | -- | -- | 1.73 | -- | -- | -- | -25.16 | -- | 38.80 | -- |
| Scancell Holdings Plc | 0.00 | -8.41m | 104.96m | 25.00 | -- | 4.63 | -- | -- | -0.0105 | -0.0105 | 0.00 | 0.0278 | 0.00 | -- | -- | 0.00 | -21.98 | -48.49 | -24.78 | -52.14 | -- | -- | -- | -- | -- | -- | 0.2598 | -- | -- | -- | -181.09 | -- | -- | -- |
| Futura Medical plc. | 0.00 | -5.87m | 106.72m | 11.00 | -- | 14.45 | -- | -- | -0.0204 | -0.0204 | 0.00 | 0.0257 | 0.00 | -- | -- | 0.00 | -52.23 | -65.78 | -57.68 | -86.83 | -- | -- | -- | -6,607.25 | -- | -- | 0.00 | -- | -- | -- | -105.85 | -- | 123.78 | -- |
| Creo Medical Group PLC | 25.90m | -28.13m | 108.92m | 316.00 | -- | 1.78 | -- | 4.21 | -0.1601 | -0.1601 | 0.1471 | 0.337 | 0.3081 | 1.84 | 4.09 | 89,303.45 | -33.47 | -- | -42.12 | -- | 46.38 | -- | -108.63 | -- | 2.19 | -215.97 | 0.1648 | -- | 166.85 | -- | -21.06 | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -1.81m | 117.42m | 6.00 | -- | 20.68 | -- | -- | -0.0273 | -0.0273 | 0.00 | 0.0834 | 0.00 | -- | -- | 0.00 | -48.39 | -49.67 | -51.44 | -54.40 | -- | -- | -- | -10,610.04 | -- | -- | 0.00 | -- | -100.00 | -- | -52.18 | -- | -- | -- |
| Allergy Therapeutics plc | 79.00m | -5.38m | 119.16m | 601.00 | -- | 2.17 | -- | 1.51 | -0.0091 | -0.0091 | 0.119 | 0.0854 | 0.8273 | 2.23 | 7.33 | 131,439.30 | -5.64 | 1.01 | -6.81 | 1.33 | 70.75 | 74.38 | -6.81 | 0.9213 | 3.16 | -13.58 | 0.153 | 0.00 | 7.83 | 11.69 | -59.11 | -- | 15.77 | -- |
| Niox Group PLC | 28.80m | 13.20m | 153.15m | 128.00 | 12.44 | 2.09 | 8.75 | 5.32 | 0.0294 | 0.0305 | 0.0635 | 0.1745 | 0.317 | 3.00 | 3.97 | 225,000.00 | 14.53 | -11.69 | 16.73 | -13.99 | 69.79 | 76.19 | 45.83 | -81.99 | 2.00 | -- | 0.0201 | -- | 16.74 | 3.85 | 108.58 | -- | -22.16 | -- |
| Animalcare Group Plc | 74.02m | -77.00k | 166.76m | 211.00 | -- | 2.12 | 20.03 | 2.25 | -0.0013 | -0.0013 | 1.23 | 1.31 | 0.6315 | 2.99 | 8.57 | 350,824.70 | -0.0657 | -- | -0.0768 | -- | 53.25 | -- | -0.104 | -- | 0.9664 | 7.16 | 0.1221 | -- | 5.01 | -- | -132.91 | -- | -- | -- |
| Bioventix PLC | 10.50m | 6.62m | 174.51m | 17.00 | 26.61 | 17.94 | 25.81 | 16.63 | 1.26 | 1.26 | 2.00 | 1.87 | 0.9615 | 2.51 | 2.78 | 617,437.10 | 60.65 | 52.37 | 65.69 | 55.55 | 92.83 | 92.30 | 63.08 | 65.29 | 10.60 | 123.63 | 0.00 | 70.90 | 5.98 | 14.65 | -6.54 | 14.01 | 65.43 | 27.46 |
Data as of Sep 28 2022. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
24.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jul 2022 | 7.53m | 11.06% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Jul 2022 | 4.17m | 6.13% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Jul 2022 | 2.91m | 4.27% |
| Jarvis Investment Management Ltd.as of 02 Jul 2022 | 790.00k | 1.16% |
| IG Markets Ltd.as of 02 Jul 2022 | 487.00k | 0.72% |
| HSBC Bank Plc (Market-Maker)as of 02 Jul 2022 | 232.00k | 0.34% |
| Rowan Dartington & Co. Ltd. (Broker)as of 02 Jul 2022 | 170.00k | 0.25% |
| Tilney Investment Management Services Ltd.as of 02 Jul 2022 | 153.00k | 0.23% |
| J. M. Finn & Co. Ltd.as of 02 Jul 2022 | 92.00k | 0.14% |
| KW Investment Management Ltd.as of 02 Jul 2022 | 90.00k | 0.13% |
More ▼
Data from 30 Sep 2020 - 02 Sep 2022Source: FactSet Research Systems Inc.
